Compared with placebo, sacubitril/valsartan treatment reduced the subsequent use of oral antihyperglycaemic treatment or insulin among patients with new-onset DM (RR = 0.68, 95% CI: 0.43–1.10), but there was no significant between-group difference (Additional file 4: Fig. S33). The gene discussed is INS; the disease is diabetes mellitus.